Core Insights - Perma-Pipe International Holdings, Inc. reported a net sales increase of 27.7% for Q2 2025, reaching $47.9 million compared to $37.5 million in the same quarter last year [1] - The growth in sales was attributed to higher sales volumes in both the Middle East and North America [1] - Gross profit for the quarter was $14.4 million, reflecting an increase of $0.9 million from $13.5 million in the prior year [1]

Core Viewpoint - Star Equity Fund's advocacy led to Servotronics agreeing to be acquired by TransDigm at a significant premium, creating substantial value for shareholders [1][2]. Group 1: Transaction Details - TransDigm will acquire all outstanding shares of Servotronics at $47.00 per share in an all-cash transaction, representing a 357% premium over the closing price on May 16, 2025 [1]. - The transaction was a result of a strategic review initiated by Servotronics' Board, influenced by Star Equity Fund's sustained pressure and advocacy [2]. Group 2: Shareholder Advocacy - Star Equity Fund's campaign included director nominations and various communications with the Board, which led to shareholder-friendly actions that may not have occurred otherwise [2]. - The advocacy highlighted that Servotronics' shares were undervalued and that its intrinsic value was higher than its trading price as a standalone public company [2]. Group 3: Stakeholder Benefits - The acquisition by TransDigm is expected to benefit all stakeholders of Servotronics, including employees and customers, according to the Portfolio Manager of Star Equity Fund [3]. - The efforts of significant shareholders and directors contributed to achieving this favorable outcome for all shareholders, including the Company's Employee Stock Ownership Plan (ESOP) [3]. Group 4: Company Background - Star Equity Fund, LP is focused on unlocking shareholder value through engagement with management teams across its portfolio companies [4]. - Star Equity Holdings, Inc. operates in three business divisions: Building Solutions, Energy Services, and Investments [5].

Core Viewpoint - Mural Oncology has decided to discontinue all clinical development of nemvaleukin alfa following unsatisfactory results from the ARTISTRY-6 and ARTISTRY-7 trials, and will explore strategic alternatives to maximize shareholder value [1][2][3] Company Developments - Mural Oncology will reduce its workforce by approximately 90% as part of its restructuring efforts [1] - The company had approximately $144.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024 [1] - Mural has engaged Lucid Capital Markets, LLC as its financial advisor to assist in exploring strategic alternatives [1][3] Clinical Trial Results - The ARTISTRY-6 trial did not achieve its primary endpoint in evaluating nemvaleukin as a monotherapy for mucosal melanoma [2] - Preliminary data from ARTISTRY-6 cohort 3, which assessed less-frequent intravenous dosing in cutaneous melanoma patients, also did not show sufficient activity to warrant continuation [2] - Interim overall survival results from the ARTISTRY-7 trial in platinum-resistant ovarian cancer contributed to the decision to halt development of nemvaleukin [2] Strategic Alternatives - Mural is considering various strategic alternatives, including potential offers for acquisition, mergers, or other business combinations [3] - The company is currently in an "offer period" as defined by the Irish Takeover Rules, which may affect the exploration of strategic alternatives [5][6] Regulatory Considerations - Mural is subject to the Irish Takeover Panel Act and must comply with specific disclosure requirements during the strategic evaluation process [5][10]

As filed with the U.S. Securities and Exchange Commission on February 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WISA TECHNOLOGIES, INC. (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Brett Moyer Chief Executive Officer WiSA Technologies, Inc. 15268 NW Greenbrier Pkwy Beaverton, OR 97006 (408) 627-4716 (Name, addre ...